Accordingly, the blocking antibodies anti-PD-1, anti-PD-Ll and anti-PD-L2, which are defined as immune checkpoint inhibitors (ICI), have been developed to stop this engagement and allow proper T cell responses to tumours [71]. The gene discussed is PDCD1LG2; the disease is neoplasm.